Solventum Doubles Down on Medtech and Plans to Separate Healthcare Information Systems
After being spun out in spring 2024, Solventum is set to chart its own course and now faces challenges to operate as a stand-alone company. It has laid out a methodical strategic path to juggle several priorities as it gets on its feet. First, management has been engaged in evaluating the end markets that Solventum currently competes in and assessing the relative strength of its product portfolio. We expect this process will result in significant restructuring. We applaud the firm’s early decision to sell its purification and filtration business. Not only did this offer Solventum an exit from a business with materially lower margins than the other three divisions, but the proceeds should help mitigate the company’s significant leverage since the spinoff.
United States